Status:

WITHDRAWN

The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome

Lead Sponsor:

Yale University

Conditions:

Ovarian Hyperstimulation Syndrome

Eligibility:

FEMALE

18-42 years

Phase:

NA

Brief Summary

This research study was designed to look at the effect of human albumin transfusion on circulating levels of Vascular Endothelial Derived Growth Factor (VEGF), a protein that is believed to be respons...

Eligibility Criteria

Inclusion

  • Infertile patients undergoing in vitro fertilization with or without ICSI
  • Estradiol \> 3000 pg/mL at the time of hCG administration
  • \>/= 20 follicles seen during ultrasound monitoring
  • Patients with polycystic ovarian syndrome

Exclusion

  • Patients with only one ovary
  • Patients with medical contraindication to human albumin (hypersensitivity, hypervolemia, cardiac insufficiency, hypertension, esophageal varices, pulmonary edema, severe anemia, renal failure)

Key Trial Info

Start Date :

September 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00617864

Start Date

September 1 2007

Last Update

February 22 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Yale Fertility Center

New Haven, Connecticut, United States, 06510

The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome | DecenTrialz